Dementia with Lewy bodies is the second most common neurodegenerative dementia affecting older adults, and there is currently no cure for this condition. However, researchers from the University of Iowa have found that males taking three commonly prescribed prostate medications may lower their risk of developing dementia with Lewy bodies. Dementia with Lewy bodies is most likely caused by deposits of a protein called alpha-synuclein in the brain. While current therapies can help manage symptoms, they do not stop the disease from progressing. This opens the need for new therapies to slow the progression or prevent the development of dementia with Lewy bodies.
In a recent study published in Neurology, researchers analyzed health information data for nearly 643,000 males taking medication to treat urinary issues caused by an enlarged prostate. They found that males taking the prostate medications terazosin, doxazosin, or alfuzosin were 40% less likely to develop dementia with Lewy bodies compared to participants taking other prostate medications. These medications activate an enzyme called PGK1, which increases energy in cells and may slow or stop the development of neurodegeneration. While the study establishes an association rather than causation, it offers a promising new avenue for reducing the risk of dementia with Lewy bodies.
Board-certified neurologist, Verna Porter, cautiously optimistic about the findings, suggests that the study opens a potential new pathway for reducing the risk of dementia with Lewy bodies. Currently, there are no drugs specifically approved to prevent or treat this condition effectively, making the need for new therapies urgent. Preventive strategies could not only enhance the quality of life for at-risk populations but also reduce the substantial economic burden on healthcare systems due to the long-term care and management required for neurodegenerative diseases.
The study findings highlight the importance of continued research into reducing the risk of dementia with Lewy bodies. Dementia with Lewy bodies is the second most common neurodegenerative dementia after Alzheimer’s disease, and finding new methods or repurposing existing drugs could address the therapeutic gap in treating this condition effectively. Further research is necessary to confirm the findings and understand the underlying mechanisms behind the potential protective effect of certain prostate medications against dementia with Lewy bodies. The hope is that these findings will lead to a treatment demonstrated in a randomized controlled trial, providing relief to individuals with this debilitating disease.
